To The Moon

Biotechnology stocks rose 1.51% among S&P 500 sectors on Wednesday, the TOP 2 gainer behind Data processing and Outsourced Servives industry(+1.91%). We have observed that several Biotech stocks have hit recen highs, for example: $ESSA Pharma(EPIX)$, $Vaxcyte, Inc.(PCVX)$,$SELLAS Life Sciences Group Inc.(SLS)$ ,$Entrada Therapeutics, Inc.(TRDA)$, $Anixa Biosciences(ANIX)$,$Actinium Pharmaceuticals(ATNM)$ (+9.72%),$Outlook Therapeutics, Inc.(OTLK)$ ,$Oyster Point Pharma(OYST)$ . 1 Month performance The above bio stocks show decent performance in October, some highlights related to the recent surge as below: Data from Tiger Trady 1.$ESSA Pharma(EPIX)$ $ESSA Pharma(EPIX)$ Surged Over 160% on Wednesday trading,ESSA Pharma announced the presentation of updated clinical data from the first two cohorts of the Phase 1/2 study of ESSA’s lead candidate EPI-7386 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The safety of the combination was favorable with a safety profile consistent with second-generation antiandrogens and no dose-limiting toxicities observed. 2. $SELLAS Life Sciences Group Inc.(SLS)$ $SELLAS Life Sciences Group Inc.(SLS)$ is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. On October11th, $SELLAS Life Sciences Group Inc.(SLS)$ announced that 3D Medicines Inc., SELLAS’ licensee for the development and commercialization of its lead clinical candidate, galinpepimut-S (GPS), in China, Hong Kong, Macau and Taiwan, has dosed the first patient in its Phase 1 clinical trial in China of GPS (3D189 in China). 3. $Vaxcyte, Inc.(PCVX)$ $Vaxcyte, Inc.(PCVX)$ stocks surge since Oct 24th after releasing topline data from a proof-of-concept study of VAX-24.The study of VAX-24 was used to evaluate the safety, tolerability and immunogenicity of the VAX-24 candidate in healthy adults that were aged between 18 to 64. VAX-24 is Vaxcyte’s 24-valent pneumococcal conjugate vaccine (PCV) which is being designed for a target addressable market worth about $7 billion each year. The 98 rating InvestorsObserver gives to $Vaxcyte, Inc.(PCVX)$ stock puts it near the top of the Healthcare sector. $(PCVX)$’s 98 overall rating means the stock scores better than 98 of all stocks. Roger Song from Jefferies Research is also extremely bullish on the stock as he expects to see Vaxcytes vaccine to play a major role in the future $8 to $10 billion dollar PCV market. Jefferies remain buyers of the stock with a $50 price target. 4. $Entrada Therapeutics, Inc.(TRDA)$ $Entrada Therapeutics, Inc.(TRDA)$ rose decent in October with 47% increase. The company had its "outperform" rating reaffirmed by investment analysts at William Blair on October 14th. $Entrada Therapeutics Inc (TRDA)$ is near the middle in its industry group according to InvestorsObserver. TRDA gets an overall rating of 55. That means it scores higher than 55 percent of stocks. COO Nathan J. Dowden sold 905 shares of the business's stock in a transaction that occurred on Thursday, October 20th. 5.$Oyster Point Pharma(OYST)$ $Oyster Point Pharma(OYST)$ is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. $(OYST)$ is near the top in its sector according toInvestorsObserver. OYST gets an overall rating of 33. 6. $Actinium Pharmaceuticals(ATNM)$ ATNM's surge on Wednesday can be attributed to the investor’s positive outlook on the recent multiple appointments to the company’s senior leadership team. Actinium Pharmaceuticals is a great speculative biotech play to look into. The company is gearing up to report topline results from the phase 3 SIERRA study, which is using Iomab-B as a preconditioning agent in patients over the age of 55 with active relapsed/refractory Acute Myeloid Leukemia (AML) prior to receiving a hematopoietic stem cell transplant (HSCT). The potential for this therapy is huge, because it could provide the capability for more patients to benefit from being able to receive HSCT. These hires add high-impact experience to the company as Actinium gears up for corporate activities post the release of top-line data from the Iomab-B SIERRA study and survival data from the Actimab-A CLAG-M combination study. The data from both the studies are expected in the fourth quarter of 2022. Prior study shows that 100% of patients who received Iomab-B were able to go on to receive BMT and engraftment without any type of delay. The 82 ratingInvestorsObservergives to ATNM stock puts it near the top of theBiotechnologyindustry. 7. $Outlook Therapeutics, Inc.(OTLK)$ $Outlook Therapeutics, Inc.(OTLK)$ and U.S. drug distributor $AmerisourceBergen(ABC)$ said at end of September, they had entered into a commercialization agreement for the anticipated launch of eye diseases treatment ONS-5010. $(OTLK)$ in late Aug. resubmitted its biologics license application to the U.S. FDA for ONS-5010 for the treatment of wet age-related macular degeneration, with other potential retinal indications to follow. $(OTLK)$ got "buy" rating by Brookline Capital Management in a research report issued to clients and investors on Early October, Chardan Capital set a "buy" rating for the company on September 13th. 8.$Anixa Biosciences(ANIX)$ $Anixa Biosciences(ANIX)$ is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the Mpro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants. The inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, said:"we are thrilled to have treated the first patient in our ongoing clinical trial. If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer." 😃If you are interested in the above-mentioned biopharmaceutical companies with good technology, welcome to add them to your watchlist😃 Some other biotech stock with great fundamental stocks are as below: Recommend to Read: Biotech Stocks Well-Positioned For Fourth Quarter: XBI, IBB, LABU $Biogen(BIIB)$ ,$Vertex Pharmaceuticals(VRTX)$ ,$Novavax(NVAX)$ ,$BioNTech SE(BNTX)$ ,$XBI(XBI)$ ,$Regeneron Pharmaceuticals(REGN)$ ,$Ionis Pharmaceuticals(IONS)$ ,$Mirati Therapeutics(MRTX)$ ,$Beam Therapeutics, Inc.(BEAM)$ ,$Alnylam Pharmaceuticals(ALNY)$ ,$Intellia Therapeutics(NTLA)$ ,$Blue Bird(BLBD)$ ,$Seagen(SGEN)$ ,$CRISPR Therapeutics AG(CRSP)$ . We will continue to update the dynamics of these excellent companies.